We are live on ! Find out more
NEXI

NexImmune, Inc. Common Stock
NEXI

Delisted

NEXI was delisted on the 11th of July, 2024.

Back to rankings

11 hedge funds and large institutions have $229K invested in NexImmune, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

63% less funds holding

Funds holding: 30 → 11 (-19)

75% less capital invested

Capital invested by funds: $921K → $229K (-$692K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 19

Holders
11
Holders Change
-19
Holders Change %
-63.33%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
5
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$5.21K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$3.46K
3
Morgan Stanley
Morgan Stanley
New York
+$54

Top Sellers

Rank Fund Capital Flow
1
AO
Allen Operations
New York
-$134K
2
RJA
Raymond James & Associates
Florida
-$67.3K
3
First Manhattan
First Manhattan
New York
-$31.3K
4
MCM
M28 Capital Management
Connecticut
-$28K
5
CG
Caprock Group
Idaho
-$21.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
SPC
1
Slate Path Capital
New York
$82.1K -$3 -1 -0%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$71.2K -$3 -1 -0%
ECG
3
EPIQ Capital Group
California
$34.7K – – –
PNC Financial Services Group
4
PNC Financial Services Group
Pennsylvania
$28.1K -$7 -2 -0%
Comerica Bank
5
Comerica Bank
Texas
$7.23K -$3 -1 -0%
TRCT
6
Tower Research Capital (TRC)
New York
$4K +$5.21K +1,545 +604%
Royal Bank of Canada
7
Royal Bank of Canada
Ontario, Canada
$2K +$3.46K +1,025 +4,659%
Morgan Stanley
8
Morgan Stanley
New York
$76 +$54 +16 +89%
BlackRock
9
BlackRock
New York
$31 – – –
Wells Fargo
10
Wells Fargo
California
$11 – – –
UBS Group
11
UBS Group
Switzerland
$2 -$3 -1 -50%
AO
12
Allen Operations
New York
– -$134K -25,437 Closed
RJA
13
Raymond James & Associates
Florida
– -$67.3K -12,825 Closed
First Manhattan
14
First Manhattan
New York
– -$31.3K -5,964 Closed
MCM
15
M28 Capital Management
Connecticut
– -$28K -5,338 Closed
Geode Capital Management
16
Geode Capital Management
Massachusetts
– -$21.6K -4,326 Closed
CG
17
Caprock Group
Idaho
– -$21.7K -4,139 Closed
Vanguard Group
18
Vanguard Group
Pennsylvania
– -$20.4K -3,893 Closed
Renaissance Technologies
19
Renaissance Technologies
New York
– -$14K -2,620 Closed
BCM
20
Bridgeway Capital Management
Texas
– -$10K -2,000 Closed
Millennium Management
21
Millennium Management
New York
– -$9.33K -1,866 Closed
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
– -$7.08K -1,417 Closed
Bank of Montreal
23
Bank of Montreal
Ontario, Canada
– -$8.18K -1,280 Closed
State Street
24
State Street
Massachusetts
– -$4.58K -917 Closed
TSS
25
Two Sigma Securities
New York
– -$4.58K -874 Closed
1
2

NEXI Hedge Fund Activity: Q4 2023 in Review

11 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in NexImmune, Inc. Common Stock (NEXI) for Q4 2023, worth a combined $229K — down 75% from $921K a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of NEXI and 0 opened new positions — a net loss of 19 holders — while 5 trimmed existing stakes and 3 added.

The largest buyer was Tower Research Capital (TRC), adding an estimated $5.21K. The largest seller was Allen Operations, exiting entirely with an estimated $134K sold.

  • 11 institutional investors held NexImmune, Inc. Common Stock (NEXI) as of Q4 2023, down from 30 in Q3 2023.
  • Funds reported $229K of NexImmune, Inc. Common Stock stock for Q4 2023, down 75% quarter-over-quarter.
  • 0 funds opened new NexImmune, Inc. Common Stock positions in Q4 2023 and 19 closed out, a net change of -19 holders.
  • The largest NexImmune, Inc. Common Stock buyer in Q4 2023 was Tower Research Capital (TRC), an estimated $5.21K added.
  • The largest NexImmune, Inc. Common Stock seller in Q4 2023 was Allen Operations, an estimated $134K sold.

Based on aggregated 13F filings for Q4 2023.